Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Nachsorge beim diffusen grosszelligen B-Zell-Lymphom – Evidenz und Empfehlung.

Vollmer K, Mamot C.

Praxis (Bern 1994). 2018 Jan;107(1):31-34. doi: 10.1024/1661-8157/a002861. Review. German. No abstract available.

PMID:
29295676
2.

"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.

Datta NR, Pestalozzi B, Clavien PA, Siebenhüner A, Puric E, Khan S, Mamot C, Riesterer O, Knuchel J, Reiner CS, Bodis S; members of the HEATPAC Trial Group.

Radiat Oncol. 2017 Nov 21;12(1):183. doi: 10.1186/s13014-017-0923-8.

3.

Diffusivity changes in bevacizumab-responding and -refractory meningioma.

Roelcke U, Berberat J, Mamot C, Remonda L.

Neuroradiology. 2017 Nov;59(11):1059-1061. doi: 10.1007/s00234-017-1923-y. Epub 2017 Sep 14. No abstract available.

PMID:
28913584
4.

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.

Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A.

J Hematol Oncol. 2017 Mar 17;10(1):70. doi: 10.1186/s13045-017-0438-7.

5.

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622.

6.

Multimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the Literature.

Thorn D, Mamot C, Krasniqi F, Metternich F, Prestin S.

Sarcoma. 2016;2016:3872768. doi: 10.1155/2016/3872768. Epub 2016 Jun 16. Review.

7.

Reply to H.J.A. Adams and T.C. Kwee.

Mamot C.

J Clin Oncol. 2016 Mar 1;34(7):766-7. doi: 10.1200/JCO.2015.65.0523. Epub 2016 Jan 11. No abstract available.

PMID:
26755512
8.

Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.

Gautschi O, Stadelmann C, Aebersold-Keller F, König K, Büttner R, Heukamp LC, Betticher D, Baumann C, Buser K, Calderoni A, Casty A, DʼAddario G, Irlé C, Mamot C, Morant R, Trojan A, Pellicioli E, Jehle-Schwertfeger S, Aebi S, Diebold J.

Oncol Res Treat. 2015;38(11):560-9. doi: 10.1159/000441367. Epub 2015 Oct 21.

PMID:
26599269
9.

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W.

Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.

PMID:
26538423
10.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S; SAKK Lung Cancer Project Group.

Lancet. 2015 Sep 12;386(9998):1049-56. doi: 10.1016/S0140-6736(15)60294-X. Epub 2015 Aug 11. Erratum in: Lancet. 2015 Sep 12;386(9998):1040.

PMID:
26275735
11.

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.

Orleth A, Mamot C, Rochlitz C, Ritschard R, Alitalo K, Christofori G, Wicki A.

J Drug Target. 2016;24(1):80-9. doi: 10.3109/1061186X.2015.1056189. Epub 2015 Jul 23.

PMID:
26204325
12.

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.

J Clin Oncol. 2015 Aug 10;33(23):2523-9. doi: 10.1200/JCO.2014.58.9846. Epub 2015 Jul 6. Erratum in: J Clin Oncol. 2015 Sep 20;33(27):3074.

PMID:
26150440
13.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S.

J Hematol Oncol. 2015 Jun 14;8:70. doi: 10.1186/s13045-015-0168-7.

14.

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P.

Eur J Cancer. 2015 Jul;51(10):1212-20. doi: 10.1016/j.ejca.2015.03.016. Epub 2015 Apr 16.

PMID:
25892646
15.

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.

Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Mamot C.

Int J Pharm. 2015 Apr 30;484(1-2):8-15. doi: 10.1016/j.ijpharm.2015.02.034. Epub 2015 Feb 18.

PMID:
25701632
16.

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.

Wicki A, Wild D, Prêtre V, Mansi R, Orleth A, Reubi JC, Rochlitz C, Mamot C, Mäcke HR, Christofori G.

EJNMMI Res. 2014 Feb 16;4(1):9. doi: 10.1186/2191-219X-4-9.

17.

Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.

Janthur WD, Cantoni N, Mamot C.

Int J Mol Sci. 2012 Nov 28;13(12):16020-45. doi: 10.3390/ijms131216020. Review.

18.

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C.

Lancet Oncol. 2012 Dec;13(12):1234-41. doi: 10.1016/S1470-2045(12)70476-X. Epub 2012 Nov 13.

PMID:
23153506
19.

Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2013 Jan;14(1):34-9. doi: 10.1016/j.cllc.2012.04.001. Epub 2012 May 24.

PMID:
22633220
20.

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C.

J Drug Target. 2012 Jun;20(5):422-32. doi: 10.3109/1061186X.2012.680960. Epub 2012 Apr 23.

PMID:
22519893
21.

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C.

Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7.

22.

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).

von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2012 Feb;23(2):531-6. doi: 10.1093/annonc/mdr126. Epub 2011 Apr 28.

23.
24.

Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?

Mamot C, Rochlitz C.

Swiss Med Wkly. 2006 Jan 7;136(1-2):4-12. Review.

PMID:
16597093
25.

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW.

Cancer Res. 2005 Dec 15;65(24):11631-8.

26.

Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain.

Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS.

Exp Neurol. 2005 Dec;196(2):381-9. Epub 2005 Sep 28.

PMID:
16197944
27.

Development of ligand-targeted liposomes for cancer therapy.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC.

Expert Opin Ther Targets. 2004 Aug;8(4):335-53. Review.

PMID:
15268628
28.

Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.

Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS.

J Neurooncol. 2004 May;68(1):1-9.

PMID:
15174514
29.

Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging.

Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS.

Cancer Res. 2004 Apr 1;64(7):2572-9.

30.

Liposome-based approaches to overcome anticancer drug resistance.

Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW.

Drug Resist Updat. 2003 Oct;6(5):271-9. Review.

PMID:
14643297
31.

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW.

Cancer Res. 2003 Jun 15;63(12):3154-61.

32.

Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer.

Mamot C, Mild G, Reuter J, Laffer U, Metzger U, Terracciano L, Boulay JL, Herrmann R, Rochlitz C.

Br J Cancer. 2003 Feb 10;88(3):420-3.

33.

Evidence for the involvement of 5-lipoxygenase products in the regulation of the expression of the proenkephalin gene in cultured astroglial cells.

Mamot C, Hildebrand B, Olenik C, Simmet T, Meyer DK.

Brain Res Mol Brain Res. 1995 Oct;33(1):79-86.

PMID:
8774948

Supplemental Content

Support Center